| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 04/05/2001 | CA2382808A1 22196, a novel human aminopeptidase |
| 04/04/2001 | EP1088900A1 Polymorphisms in the human CYP3A4, CYP3A7 and hPXR genes and their use in diagnostic and therapeutic applications |
| 04/04/2001 | EP1088104A2 Methods for treating a neurological disease by determining bche genotype |
| 04/04/2001 | EP1088100A2 Proteasomal activity |
| 04/04/2001 | EP1088092A1 Replication-defective recombinant adenovirus with mutated major late promoter |
| 04/04/2001 | EP1088079A2 Nek-related and bub1-related protein kinases |
| 04/04/2001 | EP1088077A1 Newcastle disease virus infectious clones, vaccines and diagnostic assays |
| 04/04/2001 | EP1088075A2 Aav scleroprotein, production and use thereof |
| 04/04/2001 | EP1088071A1 94 human secreted proteins |
| 04/04/2001 | EP1088067A1 Methods and compositions for modulating spermatogenesis |
| 04/04/2001 | EP1088065A2 Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
| 04/04/2001 | EP1088062A1 Transplants for myocardial scars |
| 04/04/2001 | EP1087994A1 INTERACTION OF p27(KIP1) WITH FKBP-12 |
| 04/04/2001 | EP1087792A1 NrdD |
| 04/04/2001 | EP1087788A1 Mucosal targeting immunisation |
| 04/04/2001 | EP1087785A2 Combination of radiotherapy and anti-angiogenic factors |
| 04/04/2001 | EP0983291A4 Carbamate-derivatized nucleosides and oligonucleosides |
| 04/04/2001 | EP0759695A4 A method of inducing an immune response using vaccinia virus recombinants |
| 04/04/2001 | EP0756638B1 Means for treating disorders in the blood coagulation cascade |
| 04/04/2001 | CN1290303A Use of negative regulation elements for nerve-specific expression of transgenes |
| 04/04/2001 | CN1290178A Transfection particles |
| 04/04/2001 | CN1290175A Live vaccine for human immunodeficiency virus |
| 04/03/2001 | US6211349 Protonated/acidified nucleic acids and methods of use |
| 04/03/2001 | US6211334 Cell-cycle regulatory proteins, and uses related thereto |
| 04/03/2001 | US6211164 Sensitization of tumor cells |
| 04/03/2001 | US6211163 Injection; sustained release of expressed protein |
| 04/03/2001 | US6211162 Pulmonary delivery of protonated/acidified nucleic acids |
| 04/03/2001 | US6211160 Method for tolerizing a mammalian patient to administration of gene therapy virus vectors |
| 04/03/2001 | US6210963 Autologous differentiated tissue aggregates; for the treatment of tumors; antitumor agents |
| 04/03/2001 | US6210946 Modified adenovirus containing a fiber replacement protein |
| 04/03/2001 | US6210944 Phosphoribosyl transferase from Staphylococcus aureus |
| 04/03/2001 | US6210926 Activating apoptosis in cell infected with herpes by in vitro administration of agent that inhibits infected cell protein-4 function |
| 04/03/2001 | US6210717 System for transporting genes into eukaryotic cells; used for transforming targeted host cell |
| 04/03/2001 | US6210708 Cationic virosomes as transfer system for genetic material |
| 04/03/2001 | US6210707 Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| 04/03/2001 | US6210674 GreA from Staphylococcus aureus |
| 04/03/2001 | US6210664 Method for gene transfer to the central nervous system |
| 04/03/2001 | CA2239733C Chromosome 13-linked breast cancer susceptibility gene |
| 04/03/2001 | CA2196795C Method for diagnosing a predisposition for breast and ovarian cancer |
| 03/30/2001 | WO2003044525A1 Targeting cells having mad2 mutation for treatment and/or prevention of disease |
| 03/30/2001 | WO2003042411A2 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease |
| 03/30/2001 | CA2385808A1 Targeting cells having mad2 mutation for treatment and/or prevention of disease |
| 03/30/2001 | CA2380624A1 Mutation of mec-1 related genes in the treatment of disease |
| 03/29/2001 | WO2001022092A2 Method to identify compounds which modulate fra-1 expression fils |
| 03/29/2001 | WO2001022090A1 Method for identifying compounds useful in the therapy of bone disorders |
| 03/29/2001 | WO2001021831A1 Method for identifying novel genes involved in the regulation of angiogenesis, study of said genes and use thereof for therapeutic purposes |
| 03/29/2001 | WO2001021814A1 Heparanase-2, a member of the heparanase protein family |
| 03/29/2001 | WO2001021812A1 Phosphatases which activate map kinase pathways |
| 03/29/2001 | WO2001021804A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 03/29/2001 | WO2001021802A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 03/29/2001 | WO2001021801A1 Gene treatment to enhance feed efficiency and growth rate of livestock |
| 03/29/2001 | WO2001021799A1 Traf4 associated cell cycle proteins, compositions and methods of use |
| 03/29/2001 | WO2001021793A1 p21Cip1 REMEDIES FOR RHEUMATISM |
| 03/29/2001 | WO2001021790A1 Conditional immortalisation of cells |
| 03/29/2001 | WO2001021789A1 Ribozymes used for restenosis prevention |
| 03/29/2001 | WO2001021787A1 Polypeptide humanin inhibiting nerve cell death |
| 03/29/2001 | WO2001021786A1 Method of screening disease depressant gene |
| 03/29/2001 | WO2001021773A2 Human endothelin converting enzyme-like proteins and polynucleotides encoding the same |
| 03/29/2001 | WO2001021771A2 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents |
| 03/29/2001 | WO2001021767A2 Pluripotent embryonic-like stem cells, compositions, methods and uses thereof |
| 03/29/2001 | WO2001021766A2 Methods and devices for obtaining non-hematopoietic lineage cells from hematopoietic progenitor cells |
| 03/29/2001 | WO2001021764A1 A pcra helicase of staphylococcus aureus |
| 03/29/2001 | WO2001021762A2 Method of decreasing cholesterol uptake |
| 03/29/2001 | WO2001021761A2 Recombinant adenoviral vectors and their utility in the treatment of various types of fibrosis: hepatic, renal, pulmonary, as well as hypertrophic scars |
| 03/29/2001 | WO2001021663A1 Pcna associated cell cycle proteins, compositions and methods of use |
| 03/29/2001 | WO2001021658A1 32 human secreted proteins |
| 03/29/2001 | WO2001021656A2 Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors |
| 03/29/2001 | WO2001021651A2 Novel human protease inhibitor-like proteins and polynucleotides encoding the same |
| 03/29/2001 | WO2001021220A2 Bioprosthetic heart valves |
| 03/29/2001 | WO2001021216A1 Capsid-modified recombinant adenovirus and methods of use |
| 03/29/2001 | WO2001021215A1 Cell based assay |
| 03/29/2001 | WO2001021214A1 Gene therapy for cerebrovascular disorders |
| 03/29/2001 | WO2001021213A2 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | WO2001021204A1 Therapeutic uses of m3 polypeptide |
| 03/29/2001 | WO2001021203A1 Use of an outer membrane protein a of an enterobacterium associated with a rsv immunogenic peptide for preparing vaccines for intranasal administration |
| 03/29/2001 | WO2001021202A2 Treatment of chronic inflammatory disease by inhibiting sub-groups of activated t-cells |
| 03/29/2001 | WO2001021201A2 Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen |
| 03/29/2001 | WO2001021200A1 Oral recombinant lactobacilli vaccines |
| 03/29/2001 | WO2001021184A1 Cell-based gene therapy for the pulmonary system |
| 03/29/2001 | WO2001002557A8 Neurotrophic factor receptor |
| 03/29/2001 | WO2000077026A8 49 human secreted proteins |
| 03/29/2001 | WO2000066176A3 Agent for gene therapy and for the prevention of metastases, as well as for the gene therapy of tumors |
| 03/29/2001 | WO2000061742A3 Treatment of cardiac power failure using s100 proteins |
| 03/29/2001 | WO2000056871A3 CELLS COEXPRESSING AN AMYLOID PRECURSOR PROTEIN AND AN α-SECRETASE AND THEIR USES IN TEST METHODS AND DIAGNOSTICS |
| 03/29/2001 | WO2000012741A9 Inducible expression system |
| 03/29/2001 | US20010000075 Neurotactin and uses therefor |
| 03/29/2001 | DE19946142A1 Cell-targeting vector selective for T lymphocytes, useful in gene therapy of e.g. acquired immune deficiency syndrome, encodes a single-chain variable antibody fragment |
| 03/29/2001 | CA2847143A1 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | CA2805979A1 Inhibition of secretiion from non-neuronal cells |
| 03/29/2001 | CA2793128A1 Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors |
| 03/29/2001 | CA2387695A1 A novel member of the heparanase protein family |
| 03/29/2001 | CA2386767A1 Novel human protease inhibitor-like proteins and polynucleotides encoding the same |
| 03/29/2001 | CA2385879A1 Traf4 associated cell cycle proteins, compositions and methods of use |
| 03/29/2001 | CA2385813A1 Human endothelin converting enzyme-like proteins and polynucleotides encoding the same |
| 03/29/2001 | CA2385697A1 Method for identifying novel genes involved in the regulation of angiogenesis, study of said genes and use thereof for therapeutic purposes |
| 03/29/2001 | CA2385552A1 Phosphatases which activate map kinase pathways |
| 03/29/2001 | CA2385480A1 32 human secreted proteins |
| 03/29/2001 | CA2385425A1 Pcna associated cell cycle proteins, compositions and methods of use |
| 03/29/2001 | CA2385404A1 Use of an outer membrane protein a of an enterobacterium associated with a rsv immunogenic peptide for preparing vaccines for intranasal administration |
| 03/29/2001 | CA2385377A1 Method to identify compounds useful in the therapy of bone disorders |